Pfizer Inc. (NYSE:
PFE) is one of the
Best Stocks to Buy for High Returns Heading into 2026. On October 27, Berenberg Bank analyst Luisa Hector maintained a Hold rating on Pfizer Inc. (NYSE:PFE) with a price target of $25.
Earlier on October 22, Tim Andreson from Bank of America Securities reiterated a Hold rating with a price target of $30. He noted that the cautious rating reflects the anticipated decline in the company’s revenue and EPS estimates for the coming years.
In addition, the COVID product sales are also anticipated to decrease in the United States. Anderson noted that the company’s long-term growth outlook is clouded with uncertainties, which include patent expirations and competitive pressure from other franchises.
Pfizer Inc. (NYSE:PFE) is set to release its fiscal third quarter results on November 4, 2025. During the second quarter earnings call, management reaffirmed its full-year revenue guidance of $61 billion to $64 billion and raised the adjusted diluted EPS guidance by $0.10.
However, management noted that the fiscal third quarter results are expected to include a one-time expense of $1.35 billion charges related to a licensing deal with 3SBio, Inc. The expense is expected to reduce the quarterly earnings per share by around $0.20.
Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines.
While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at
Insider Monkey.
